A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Clinical Efficacy of Anti-Tigitmab BAT6005 Injection in Patients With Advanced Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 6005 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Bio-Thera Solutions

Most Recent Events

07 Feb 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
29 Dec 2021 According to Bio-Thera Solutions media release, dosing has begun in this trial.
16 Nov 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight